Oral Estradiol Year-1 Outcomes: What Real Users Actually Experience

What is documented for the first year

The oral estradiol tablet label lists reactions reported with estrogen therapy without rates. They include breast tenderness, nausea and bloating, headache and dizziness, changes in vaginal bleeding, edema, weight change, mood changes, gallbladder disease and changes in libido [1].

Clot risk is highest in year one

A BMJ systematic review and meta-analysis pooled eight observational studies and nine randomized trials of hormone therapy. These studies looked at oral estrogen as a class, not estradiol alone. In the observational data, the odds ratio for a first venous thromboembolism among current oral estrogen users was 2.5 (95% CI 1.9 to 3.4). It was higher in the first year (4.0, 2.9 to 5.7) than after it (2.1, 1.3 to 3.8) [2]. The French ESTHER case-control study, with 271 cases and 610 matched controls, reported an odds ratio of 4.2 (1.5 to 11.6) for oral estrogen and 0.9 (0.4 to 2.1) for transdermal estrogen [3]. Both are observational.

Bleeding, dosing and the boxed warning

The label says unopposed estrogen raises endometrial cancer risk in a woman with a uterus, and that adding a progestin reduces the risk of endometrial hyperplasia. It puts the unopposed risk at about 2- to 12-fold that of non-users and notes that most studies show no significant increase with use under one year [1].

The label says a progestin should also be started in a postmenopausal woman with a uterus, and that a woman without a uterus does not need one. It gives the usual initial dose as 1 to 2 mg of estradiol daily, adjusted to symptoms, with cyclic administration (for example 3 weeks on, 1 week off) and reevaluation at 3 to 6 month intervals [1].

The oral tablet label still carries the older boxed warning. FDA's list of six updated labels, current as of 2026-02-12, does not include oral estradiol tablets or estradiol patches [1][5][6].

What the trials measured

ELITE is a randomized trial, not a first-year study. 567 women were included in the analysis after a mean treatment duration of 57 months. They received oral 17-beta estradiol 1 mg a day or placebo, with cyclic micronized progesterone vaginal gel for women with a uterus. The verbal memory difference was -0.06 (95% CI -0.22 to 0.09, p=0.33), with no significant difference in executive function or global cognition [7].

What the label says to watch for

The label says estrogens should be discontinued immediately if myocardial infarction, stroke, venous thrombosis or pulmonary embolism occurs or is suspected. It also says that, if feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery with increased thromboembolism risk or during prolonged immobilization [1].